Insulin increases gelatinase activity in rat glomerular mesangial cells via ERK- and PI-3 kinase-dependent signalling

Diabetes, Obesity and Metabolism

Volumn 8, Issue 3, 2006, Pages 281-288

  Lee, M P S ^a   Sweeney, Gary ^a  

^a YORK UNIVERSITY   (Canada)

Author keywords

Diabetic nephropathy; Extracellular matrix; Gelatinase; Insulin; Matrix metalloproteinases

Indexed keywords

2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; 2 MORPHOLINO 8 PHENYLCHROMONE; 4 (4 FLUOROPHENYL) 2 (4 HYDROXYPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; GELATIN; GELATINASE; GELATINASE A; HUMAN INSULIN; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEINASE; RAPAMYCIN;

ANIMAL CELL; ARTICLE; DIABETIC NEPHROPATHY; DISEASE ASSOCIATION; DRUG MECHANISM; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME ASSAY; EXTRACELLULAR MATRIX; INSULIN RESISTANCE; MESANGIUM CELL; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PATHOGENESIS; PROTEIN EXPRESSION; RAT; RAT STRAIN; SIGNAL TRANSDUCTION; WESTERN BLOTTING; ZYMOGRAPHY;

EID: 33645462020     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/j.1463-1326.2005.00502.x     Document Type: Article

References (31)

1. Ziyadeh FN. The extracellular matrix in diabetic nephropathy. Am J Kidney Dis 1993; 22: 736-744.
2. McLennan SV, Fisher E, Martell SY et al. Effects of glucose on matrix metalloproteinase and plasmin activities in mesangial cells: Possible role in diabetic nephropathy. Kidney Int Suppl 2000; 77: S81-S87.
3. Sharma K, Ziyadeh FN. Hyperglycemia and diabetic kidney disease. The case for transforming growth factor-beta as a key mediator. Diabetes 1995; 44: 1139-1146.
4. Lehmann R, Schleicher ED. Molecular mechanism of diabetic nephropathy. Clin Chim Acta 2000; 297: 135-144.
5. Nerlich AG, Schleicher ED, Wiest I, Specks U, Timpl R. Immunohistochemical localization of collagen VI in diabetic glomeruli. Kidney Int 1994; 45: 1648-1656.
6. Visse R, Nagase H. Matrix metalloproteinases and tissue inhibitors of metalloproteinases: Structure, function, and biochemistry. Circ Res 2003; 92: 827-839.
7. Bode W, Fernandez-Catalan C, Tschesche H, Grams F, Nagase H, Maskos K. Structural properties of matrix metalloproteinases. Cell Mol Life Sci 1999; 55: 639-652.
8. Nagase H, Woessner JF Jr. Matrix metalloproteinases. J Biol Chem 1999; 274: 21491-21494.
9. Inoki K, Haneda M, Maeda S, Koya D, Kikkawa R. TGF-beta 1 stimulates glucose uptake by enhancing GLUT1 expression in mesangial cells. Kidney Int 1999; 55: 1704-1712.
10. Heilig CW, Concepcion LA, Riser BL, Freytag SO, Zhu M, Cortes P. Overexpression of glucose transporters in rat mesangial cells cultured in a normal glucose milieu mimics the diabetic phenotype. J Clin Invest 1995; 96: 1802-1814.
11. Nakamura T, Fukui M, Ebihara I, Osada S, Tomino Y, Koide H. Abnormal gene expression of matrix metalloproteinases and their inhibitor in glomeruli from diabetic rats. Ren Physiol Biochem 1994; 17: 316-325.
12. Schwartz J, Huo JS, Piwien-Pilipuk G. Growth hormone regulated gene expression. Minerva Endocrinol 2002; 27: 231-241.
13. Yang SH, Sharrocks AD, Whitmarsh AJ. Transcriptional regulation by the MAP kinase signaling cascades. Gene 2003; 320: 3-21.
14. Hibbs MS, Hasty KA, Seyer JM, Kang AH, Mainardi CL. Biochemical and immunological characterization of the secreted forms of human neutrophil gelatinase. J Biol Chem 1985; 260: 2493 -2500.
15. Lohi J, Harvima I, Keski-Oja J. Pericellular substrates of human mast cell tryptase: 72,000 dalton gelatinase and fibronectin. J Cell Biochem 1992; 50: 337-349.
16. Cheatham B, Vlahos CJ, Cheatham L, Wang L, Blenis J, Kahn CR. Phosphatidylinositol 3-kinase activation is required for insulin stimulation of pp70, S6 kinase, DNA synthesis, and glucose transporter translocation. Mol Cell Biol 1994; 14: 4902-4911.
17. Moule SK, Edgell NJ, Welsh GI, Diggle TA, Proud CG, Denton RM. Studies with wortmannin indicate that insulin stimulation of lipogenesis involves multiple signalling pathways. Biochem Soc Trans 1995; 23: 206S.
18. English JM, Cobb MH. Pharmacological inhibitors of MAPK pathways. Trends Pharmacol Sci 2002; 23: 40-45.
19. Chung J, Kuo CJ, Crabtree GR, Blenis J. Rapamycin-FKBP specifically blocks growth-dependent activation of and signaling by the 70 kd S6 protein kinases. Cell 1992; 69: 1227-1236.
20. McLennan SV, Death AK, Fisher EJ, Williams PF, Yue DK, Turtle JR. The role of the mesangial cell and its matrix in the pathogenesis of diabetic nephropathy. Cell Mol Biol (Noisy-le-grand) 1999; 45: 123-135.
21. Aumailley M, Gayraud B. Structure and biological activity of the extracellular matrix. J Mol Med 1998; 76: 253-265.
22. McLennan SV, Kelly DJ, Cox AJ et al. Decreased matrix degradation in diabetic nephropathy: Effects of ACE inhibition on the expression and activities of matrix metalloproteinases. Diabetologia 2002; 45: 268-275.
23. Abrass CK. Diabetic nephropathy. Mechanisms of mesangial matrix expansion. West J Med 1995; 162: 318-321.
24. Goldstein BJ. Insulin resistance as the core defect in type 2 diabetes mellitus. Am J Cardiol 2002; 90: 3G-10G.
25. Marti HP, Lovett DH. Current aspects in the pathogenesis and therapy of glomerulonephritis: Significance of glomerular metalloproteinases Schweiz Med Wochenschr 1992; 122: 1701-1707.
26. Diamant M, Hanemaaijer R, Verheijen JH, Smit JW, Radder JK, Lemkes HH. Elevated matrix metalloproteinase-2 and -9 in urine, but not in serum, are markers of type 1 diabetic nephropathy. Diabet Med 2001; 18: 423-424.
27. Lupia E, Elliot SJ, Lenz O et al. IGF-1 decreases collagen degradation in diabetic NOD mesangial cells: Implications for diabetic nephropathy. Diabetes 1999; 48: 1638-1644.
28. Zaoui P, Cantin JF, Alimardani-Bessette M et al. Role of metalloproteases and inhibitors in the occurrence and progression of diabetic renal lesions. Diabetes Metab 2000; 26 (Suppl. 4): 25-29.
29. Kanauchi M, Nishioka H, Kawano T, Uyama H, Shiiki H, Dohi K. Matrix metalloproteinase-2 and mesangiolysis in diabetic nephropathy. Nephron 1999; 83: 174-175.
30. Del Prete D, Anglani F, Forino M et al. Down-regulation of glomerular matrix metalloproteinase-2 gene in human NIDDM. Diabetologia 1997;40: 1449-1454.
31. Zhang D, Bar-Eli M, Meloche S, Brodt P. Dual regulation of MMP-2 expression by the type 1 insulin-like growth factor receptor: The phosphatidylinositol 3-kinase/Akt and Raf/ERK pathways transmit opposing signals. J Biol Chem 2004; 279: 19683-19690.